Blog
Celebrating the Hamilton Grand Opening
On October 17, 2024, OmniaBio welcomed over 200 guests to our Hamilton facility commemorating the opening of our purpose-built, commercial cell and gene therapy manufacturing and AI centre of excellence.
BLOG
By addressing challenges related to cost, production efficiency, and patient safety, allogeneic CAR T cell therapies have the potential to make these therapies more accessible and consistent.
BLOG
iPSCs are created by reprogramming differentiated somatic cells, which allows them to exhibit properties similar to embryonic stem cells. From a scale-up and manufacturing perspective, groups need the right support to achieve their goals in a time-efficient and cost-effective manner.
BLOG
This blog will explore how developing customized solutions for system closure and process automation solves key technical bottlenecks, advances the manufacturing of, and ultimately patient access to, these life-saving medicines.
